Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Parmodia Again Tops December GP Rep Promotion Ranking, Dayvigo 5th Month Title Holder for HP
February 1, 2024
- Axcelead DDP Looks to Lift Overseas Sales Ratio to 80%: President
January 31, 2024
- Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout
January 31, 2024
- Gilead Files Trodelvy for Triple-Negative Breast Cancer in Japan
January 31, 2024
- US FDA Approves Additional CIDP Use for Takeda’s Gammagard Liquid
January 31, 2024
- Takeda’s Hyqvia Nabs European Approval for CIDP Maintenance Therapy
January 31, 2024
- Susmed Drops Reimbursement Request for Insomnia App
January 30, 2024
- Enhertu Gets FDA’s Priority Review for Pan-Tumor Indication: Daiichi Sankyo
January 30, 2024
- Astellas/Pfizer Seeks 1st Line Bladder Cancer Use for Padcev/Keytruda in EU
January 30, 2024
- Eisai Resubmits Ultra-High Dose Mecobalamin in Japan for ALS
January 29, 2024
- Mitsubishi Tanabe Newly Pledges 100 Billion Yen for GHIT Fund
January 29, 2024
- Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
January 29, 2024
- Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
- Shionogi Partners with Niremia Collective to Fund Well-Being Tech Startups
January 26, 2024
- BlueRock In-Licenses Fujifilm’s iPSC Therapy for Ocular Disease
January 25, 2024
- Kyowa Kirin Closes Acquisition of UK Gene Therapy Player Orchard
January 25, 2024
- Takeda’s Cuvitru Now Available in Japan as Its First SC Immunoglobulin
January 25, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
- Astellas to Discontinue IBS Med Colonel in Product Consolidation
January 24, 2024
- Astellas to Transfer Distribution Rights for Antibacterial Geninax to Taisho
January 24, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…